AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) headquartered in Redwood City, will host a conference call for the investment community to discuss the 2Q20 earnings result on 10th August 2020 at 4:30 PM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.acelrx.com
Earnings Expectation
AcelRx Pharmaceuticals, Inc. is reporting second quarter financial results on Monday 10th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, ACRX is expected to report 2Q20 loss of $ 0.14 per share from revenue of $ 2.02 million.
For the full year, analysts anticipate top line of $ 17.03 million, while looking forward to loss of $ 0.53 per share bottom line.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.
